New off-the-shelf cell therapy targets aggressive childhood cancers

First projects backed by C-Further consortium to develop better treatments for children with cancer

Children and young people diagnosed with aggressive cancers could benefit from potential new treatments from two pioneering projects led by United Kingdom (UK) and United States (US) researchers. C-Further has partnered with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute and Mass General Brigham to advance the drug, CF-012, for the potential treatment of Ewing sarcoma, a rare and aggressive type of bone cancer. In…

New off-the-shelf cell therapy targets aggressive childhood cancers

First CF-012 and CF-033 projects target Ewing sarcoma and other childhood cancers. $40m in backing, with proposals invited through March 13, 2026.